68 related articles for article (PubMed ID: 7819582)
21. Immunohistochemical studies of early breast cancer evolution.
Allred DC; O'Connell P; Fuqua SA; Osborne CK
Breast Cancer Res Treat; 1994; 32(1):13-8. PubMed ID: 7819582
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers in early breast neoplasia.
Allred DC; O'Connell P; Fuqua SA
J Cell Biochem Suppl; 1993; 17G():125-31. PubMed ID: 8007690
[TBL] [Abstract][Full Text] [Related]
23. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
24. Molecular genetic studies of early breast cancer evolution.
O'Connell P; Pekkel V; Fuqua S; Osborne CK; Allred DC
Breast Cancer Res Treat; 1994; 32(1):5-12. PubMed ID: 7819586
[TBL] [Abstract][Full Text] [Related]
25. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Sasano H
Jpn J Cancer Res; 2000 Nov; 91(11):1169-76. PubMed ID: 11092983
[TBL] [Abstract][Full Text] [Related]
26. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
27. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis.
Watson PH; Safneck JR; Le K; Dubik D; Shiu RP
J Natl Cancer Inst; 1993 Jun; 85(11):902-7. PubMed ID: 8492318
[TBL] [Abstract][Full Text] [Related]
28. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
Poller DN; Snead DR; Roberts EC; Galea M; Bell JA; Gilmour A; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1993 Jul; 68(1):156-61. PubMed ID: 8100443
[TBL] [Abstract][Full Text] [Related]
29. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein.
Poller DN; Roberts EC; Bell JA; Elston CW; Blamey RW; Ellis IO
Hum Pathol; 1993 May; 24(5):463-8. PubMed ID: 8098318
[TBL] [Abstract][Full Text] [Related]
30. Molecular aspects of early stages of breast cancer progression.
Smith HS; Lu Y; Deng G; Martinez O; Krams S; Ljung BM; Thor A; Lagios M
J Cell Biochem Suppl; 1993; 17G():144-52. PubMed ID: 8007693
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for breast cancer in women with proliferative breast disease.
Dupont WD; Page DL
N Engl J Med; 1985 Jan; 312(3):146-51. PubMed ID: 3965932
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study.
Bartow SA; Pathak DR; Black WC; Key CR; Teaf SR
Cancer; 1987 Dec; 60(11):2751-60. PubMed ID: 3677009
[TBL] [Abstract][Full Text] [Related]
33. ras p21 expression in the progression of breast cancer.
Fromowitz FB; Viola MV; Chao S; Oravez S; Mishriki Y; Finkel G; Grimson R; Lundy J
Hum Pathol; 1987 Dec; 18(12):1268-75. PubMed ID: 3315956
[TBL] [Abstract][Full Text] [Related]
34. Cell kinetics of histologic variants of in situ breast carcinoma.
Meyer JS
Breast Cancer Res Treat; 1986; 7(3):171-80. PubMed ID: 3022849
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
